NCT03097601View on ClinicalTrials.gov

ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

June 2, 2016

Primary Completion Date

December 30, 2019

Study Completion Date

December 30, 2019

Conditions
Metastatic Kidney Cancers
Interventions
DIAGNOSTIC_TEST

ELR+CXCL cytokines levels are of sunitinib response

Demonstrate on independent cohorts of patients that ELR+CXCL cytokines levels are of sunitinib response

Trial Locations (1)

06189

Centre Antoine LACASSAGNE, Nice

All Listed Sponsors
collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

lead

Centre Antoine Lacassagne

OTHER

NCT03097601 - ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib | Biotech Hunter | Biotech Hunter